2018 AANS Annual Scientific Meeting-763. Antitumor Efficacy Of Anti-PDL-1 In ACTH-Secreting Pituitary Adenomas: An Immunotherapeutic Approach For Cushing’s Disease

763. Antitumor Efficacy Of Anti-PDL-1 In ACTH-Secreting Pituitary Adenomas: An Immunotherapeutic Approach For Cushing’s Disease

Back to course

Video Transcription

Video Summary

In this video, Dr. Anna Kemeny presents her research on the anti-tumor efficacy of anti-PD-L1 therapy in ACTH CPD-P2-3 adenovirus. Pituitary adenomas are common intracranial tumors that can cause systemic comorbidities. Surgical intervention is the primary treatment, but it has a recurrence rate of 25% in five years. Immunotherapy targeting PD-L1, a protein overexpressed by tumor cells, has shown success in various solid tumors. The researchers found that PD-L1 is expressed in human pituitary adenomas and confirmed this in a murine model. They demonstrated that anti-PD-L1 therapy reduced tumor growth and increased survival. This study provides a potential new treatment modality for Cushing's disease.

Asset Caption

Hanna Kemeny

Keywords

anti-PD-L1 therapy

pituitary adenomas

immunotherapy

tumor growth

Cushing's disease